The world-renowned infectious disease researcher was profiled in The New York Times for his role in developing Dificid, the first new medicine in 25 years approved to treat diarrhea caused by ...
Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback